TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03606538: MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Sponsor: Resilient Pharmaceuticals · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,454,128

Rescue Site Savings

+$2,280,176

Unlock Full NCT03606538 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03606538 Rescue Dossier →